Non-small cell lung cancer p53 and estrogen receptor expression and its clinical significance and correlation.doc

 PAGE \* MERGEFORMAT 6 Non-small cell lung cancer p53 and estrogen receptor expression and its clinical significance and correlation [Abstract] Objective To investigate the non-small cell lung cancer (NSCLC) in the p53 protein and estrogen receptor (ER) expression and clinical pathological correlation. Methods Immunohistochemical S  P were detected 63 cases of NSCLC cancer tissues and 20 cases of benign lesions in the p53, ER expression. Results p53 positive rate was 52.3% (33/63), in which the positive rate of squamous cell carcinoma was 55.2% (21/38) and adenocarcinoma positive rate of 48.0% (12/25), while 20 cases of benign lesions were not detected in p53 positive expression. ER positive rate was 74.6% (47/63), in which the positive rate of squamous cell carcinoma 65.8% (25/38), adenocarcinoma positive rate of 88.0% (22/25), in 20 patients with no ER expression in benign lesions. p53, ER positive expression with sex, age, histological type and pathological grade no significant correlation. Conclusions p53 and ER expression in NSCLC may be regarded as two independent factors and their respective participation in an independent manner the occurrence and development of lung cancer. In the ER-positive cases, supplemented by clinical endocrine treatment can be effective. [Keywords:] non-small cell lung cancer; p53 protein; estrogen receptor; expression ABSTRACT: Objective To investigate the relationships between expression of tumor suppressor gene P53, estrogen receptor (ER) and clinic pathology in human non small lung cancer (NSCLC). Methods The expression of P53 protein and ER in 63 NSCLC specimen and 20 specimen from patients with benign lung disease were detected by SP immunonhistochemistry method.Results 52.3% tumor tissues had positive P53 staining, and the positive rate in squamous cell carcinoma and adenocarcinoma was 55.2% and 48.0%, respectively; 74.6% tumor tissues had positive expression of ER, and the positive rate in squamous cell carcinoma an